These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36820147)

  • 21. Analysis of the role of Frizzled 2 in different cancer types.
    Zhou M; Sun X; Zhu Y
    FEBS Open Bio; 2021 Apr; 11(4):1195-1208. PubMed ID: 33565732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of
    Wei C; Zhao Y; Ji T; Sun Y; Cai X; Peng X
    Front Oncol; 2022; 12():865409. PubMed ID: 35480115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma.
    Wang Z; Zheng W; Chen Z; Wu S; Chang H; Cai M; Cai H
    Front Oncol; 2022; 12():1055376. PubMed ID: 36531056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
    Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
    Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
    [No Abstract]   [Full Text] [Related]  

  • 25. Pan-Cancer Analysis of Microfibrillar-Associated Protein 2 (MFAP2) Based on Bioinformatics and qPCR Verification.
    Qiu Z; Xin M; Wang C; Zhu Y; Kong Q; Liu Z
    J Oncol; 2022; 2022():8423173. PubMed ID: 35211173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-Cancer Analyses Reveal Oncogenic and Immunological Role of PLOD2.
    Xu Q; Kong N; Zhao Y; Wu Q; Wang X; Xun X; Gao P
    Front Genet; 2022; 13():864655. PubMed ID: 35586565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 32. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
    Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
    Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
    [No Abstract]   [Full Text] [Related]  

  • 33. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
    Zhao Q; Zhang Z; Wu Y
    Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-cancer analysis of forkhead box Q1 as a potential prognostic and immunological biomarker.
    Dong Q; Yan L; Xu Q; Hu X; Yang Y; Zhu R; Xu Q; Yang Y; Wang B
    Front Genet; 2022; 13():944970. PubMed ID: 36118871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
    Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
    Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effects of Differentially-Expressed Homeobox Family Genes on the Prognosis and HOXC6 on Immune Microenvironment Orchestration in Colorectal Cancer.
    Qi L; Ye C; Zhang D; Bai R; Zheng S; Hu W; Yuan Y
    Front Immunol; 2021; 12():781221. PubMed ID: 34950145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma.
    Wang M; Yang X; Meng Y; Jin Z; Cao J; Xiong L; Xiong Z
    Int Immunopharmacol; 2023 Feb; 115():109660. PubMed ID: 36623412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma.
    Shang BB; Chen J; Wang ZG; Liu H
    PeerJ; 2021; 9():e12315. PubMed ID: 34754620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.